PuSH - Publication Server of Helmholtz Zentrum München

Mbuya, W.* ; Horvath, A.* ; Held, K. ; Maganga, L.* ; Hoelscher, M. ; Bekker, L.G.* ; Duerr, A.* ; Moodie, Z.* ; Churchyard, G.* ; Keefer, M.C.* ; Viegas, E.* ; Moog, C.* ; Geldmacher, C. ; Chachage, M.*

Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses.

Front. Immunol. 16:1601865 (2025)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
BACKGROUND: Sex, race and geographic location may affect vaccine-induced immune responses, yet few preventive HIV vaccine trials have systematically evaluated such effects. The main objective of this study was therefore to examine the role of these factors on vaccine-induced HIV-specific immune responses within the HVTN 204 trial. This randomized, double-blinded, placebo-controlled phase 2 trial enrolled 480 Black and Caucasian adults from Africa and the Americas, who received a trivalent DNA-HIV-1 vaccine prime followed by a rAd5 vector HIV-1 vaccine boost. METHODS: Available serum samples from baseline and four weeks after the final vaccination boost from Black (n=85, 59% female) and Caucasian (n=49, 51% female) HVTN 204 vaccine recipients from South Africa and the United States of America were studied using an Enzyme-Linked Immunosorbent Assay to determine titers of Envelope-specific IgG1, IgG3 and IgA antibodies. Recognition of linear Envelope peptide-specific IgG responses was mapped in a randomly selected subgroup analysis using a custom-designed peptide microarray (n = 41, 49% female). Associations between vaccine-induced Envelope-specific antibody responses and sex assigned at birth (female or male), race and geographic location were then analyzed by the Mann-Whitney U test, Fisher's exact test and multivariate logistic regression. RESULTS: Four weeks post-final vaccination boost, we observed that Envelope-specific antibody titers were significantly increased for IgG1 but reduced for IgA in females (female vs. male median titer: 900 vs. 300, p=0.030 and <100 vs. 100, p=0.007, respectively). Multivariate logistic regression confirmed that female sex increased the odds for higher Envelope-specific IgG1 and low IgA titers compared to males. In terms of antibody epitopes, the V2 region was more frequently recognized in females than males (p=0.008). Race and geographic location had no apparent influence on antibody isotype titers investigated. CONCLUSION: Female sex was associated with higher vaccine-induced IgG Envelope-specific binding antibody titers and recognition of V2 region of HIV Envelope in HVTN 204 volunteers. No such associations were detected for race or geographic location. Understanding biological factors driving these sex-based differences may improve the design of a new generation of HIV vaccine candidates.
Impact Factor
Scopus SNIP
Altmetric
5.900
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Hiv-1 ; Hvtn 204 ; Antibody ; Race ; Sex ; Vaccines; Cell Responses; Efficacy; Individuals; Protection; Outcomes; Plasma; Region; Gp120; Alvac
Language english
Publication Year 2025
HGF-reported in Year 2025
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Quellenangaben Volume: 16, Issue: , Pages: , Article Number: 1601865 Supplement: ,
Publisher Frontiers
Publishing Place Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland
Reviewing status Peer reviewed
Institute(s) Research Unit Global Health (UGH)
POF-Topic(s) 30205 - Bioengineering and Digital Health
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-540001-003
Grants National Institutes of Health (NIH)
DZIF MD Stipend
German Center for Infection Research (DZIF)
EC Horizon 2020
EHVA
National Institute of Allergy and Infectious Diseases (NIAID), through HVTN Initiatives Program
Scopus ID 105018287347
PubMed ID 41063982
Erfassungsdatum 2025-10-27